We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.17B
1-Year Est. Return 92.19%
This Fund
S&P 500
This Quarter Est. Return
+11.01%
1 Year Est. Return
+92.19%
3 Year Est. Return
+240.57%
5 Year Est. Return
+377.11%
10 Year Est. Return
+3,179.38%
AUM
$3.4B
AUM Growth
+$210M
Cap. Flow
-$219M
Cap. Flow %
-6.45%
Top 10 Hldgs %
33.65%
Holding
105
New
22
Increased
13
Reduced
16
Closed
20

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$107M
2
CRBU icon
Caribou Biosciences
CRBU
+$100M
3
CYTK icon
Cytokinetics
CYTK
+$43.4M
4
SOPH icon
SOPHiA GENETICS
SOPH
+$35.6M
5
AZN icon
AstraZeneca
AZN
+$33.6M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$166M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$68.5M
3
MYOV
Myovant Sciences Ltd.
MYOV
+$43.5M
4
BIIB icon
Biogen
BIIB
+$37.8M
5
BAX icon
Baxter International
BAX
+$36.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86.76%
2 Miscellaneous 12.97%
3 Financials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$171M 5.03%
1,561,290
-26,058
-2% -$2.71M
OM icon
2
Outset Medical
OM
$67.5M
$147M 4.31%
197,781
– –
LLY icon
3
Eli Lilly
LLY
$1.02T
$121M 3.57%
525,455
– –
RCUS icon
4
Arcus Biosciences
RCUS
$3.78B
$120M 3.52%
3,431,010
-67,250
-2% -$2.09M
CYTK icon
5
Cytokinetics
CYTK
$10.1B
$113M 3.32%
3,159,701
+1,472,689
+87% +$43.4M
ABBV icon
6
AbbVie
ABBV
$453B
$98.9M 2.91%
916,496
-10,327
-1% -$1.18M
ERAS icon
7
Erasca
ERAS
$5.66B
$98.2M 2.89%
+5,191,405
New +$107M
HCA icon
8
HCA Healthcare
HCA
$87.7B
$94.8M 2.79%
390,507
– –
MYGN icon
9
Myriad Genetics
MYGN
$305M
$92.8M 2.73%
2,872,918
-216,234
-7% -$7.18M
CRBU icon
10
Caribou Biosciences
CRBU
$168M
$88.2M 2.59%
+4,092,309
New +$100M
IQV icon
11
IQVIA
IQV
$44.1B
$85.7M 2.52%
357,916
– –
AVTR icon
12
Avantor
AVTR
$10.1B
$85.1M 2.5%
2,079,657
– –
NBIX icon
13
Neurocrine Biosciences
NBIX
$15.8B
$82.9M 2.44%
864,079
-251,925
-23% -$23.8M
UHS icon
14
Universal Health Services
UHS
$10B
$72.1M 2.12%
520,786
+33,786
+7% +$5.11M
MCK icon
15
McKesson
MCK
$106B
$69.6M 2.05%
349,181
-7,050
-2% -$1.41M
GILD icon
16
CALL
Gilead Sciences
GILD
$187B
$67.3M 1.98%
+963,700
New +$67.7M
DVAX
17
DELISTED
Dynavax Technologies
DVAX
$63.1M 1.85%
3,283,570
+292,800
+10% +$3.89M
SGEN
18
DELISTED
Seagen Inc. Common Stock
SGEN
$61.9M 1.82%
364,630
-118,355
-25% -$18.4M
UNH icon
19
CALL
UnitedHealth
UNH
$356B
$61.4M 1.81%
+157,200
New +$65.1M
CNC icon
20
Centene
CNC
$33.1B
$61.4M 1.8%
984,871
-60,602
-6% -$4.05M
XLF icon
21
CALL
State Street Financial Select Sector SPDR ETF
XLF
$55.5B
$60.1M 1.77%
+1,602,200
New +$59.9M
EW icon
22
Edwards Lifesciences
EW
$51.8B
$58.1M 1.71%
513,005
– –
UNH icon
23
UnitedHealth
UNH
$356B
$56.8M 1.67%
145,295
– –
HUM icon
24
Humana
HUM
$48.2B
$54.3M 1.6%
139,420
-2,986
-2% -$1.27M
DHR icon
25
Danaher
DHR
$146B
$53.5M 1.57%
198,178
– –
1
2 3 4

Similar funds

JC
Jacobs & Co San Francisco, California $1.17B AUM 37.3% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.16B AUM 28.78% 1-Year Est. Return
MK
MASTERINVEST Kapitalanlage Vienna $1.16B AUM 40% 1-Year Est. Return
HCP
Hiddenite Capital Partners New York $1.16B AUM 95.58% 1-Year Est. Return
EC
Estate Counselors Thiensville, Wisconsin $1.16B AUM 21.97% 1-Year Est. Return
M
MOTCO San Antonio, Texas $1.17B AUM 23.84% 1-Year Est. Return
CCM
Coliseum Capital Management Rowayton, Connecticut $1.16B AUM 23.26% 1-Year Est. Return
VFP
Verus Financial Partners Richmond, Virginia $1.17B AUM 15.91% 1-Year Est. Return

PFM Health Sciences's Q3 2021 Portfolio in Review

As of Q3 2021, PFM Health Sciences held 105 positions worth $3.4B, up 6.6% from $3.19B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

PFM Health Sciences withdrew a net $219M in Q3 2021, closing 20 positions and reducing 16 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $166M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 93% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, PFM Health Sciences opened a new position in Erasca worth $98.2M.

  • PFM Health Sciences's largest Q3 2021 buy was Erasca: 5,191,405 shares worth $98.2M.
  • PFM Health Sciences added most to Cytokinetics in Q3 2021, an estimated $43.4M increase.
  • PFM Health Sciences's biggest Q3 2021 reduction was Biogen, cutting an estimated $37.8M.
  • PFM Health Sciences fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $166M.
  • PFM Health Sciences's ten largest holdings make up 34% of its $3.4B portfolio in Q3 2021.
  • PFM Health Sciences opened 22 new positions and closed 20 in Q3 2021.
  • PFM Health Sciences's portfolio value rose 6.6% quarter-over-quarter to $3.4B.

Based on PFM Health Sciences's 13F filing for Q3 2021, filed 15 Nov 2021.